Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders. We report the case of a patient with an acquired Factor VIII inhibitor, who was on a prophylactic dose of tranexamic acid because of recurrent bleeding episodes and developed a pulmonary embolism. Although studies using tranexamic acid have not shown a definite increased risk for the development of venous thrombosis, this is the likely cause of the pulmonary embolism in this patient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1034/j.1600-0609.2002.01607.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!